Table 2. Genotypic and phenotypic... | American Society of Hematology

Table 2.

Genotypic and phenotypic features of B-CLL tumors withTP53 mutations

Tumor	ATM protein	ATM mutation	TP53mutation (amino acid change)	Germline/ somatic	Allelic status	p53/MDM2/p21 induction	VH/D/J family	% Homology	Stage	Th
B-CLL9	N	WT	C844T	Acq	Hemizygous	D	V3-30.3	100	B	C/P
			(R282W)				D3-22/J6
B-CLL43^*	N	WT	C472G	Acq	Hemizygous	D	VH5-51	100	C	CPFCy
			(R158G)				D3-10
B-CLL44^*	N	WT	G412C	Acq	Hemizygous	ND	V1-69	99.6	C	NA
			(A138P)				Dns/J5
B-CLL45	N	WT	1207ins133bp	Acq	Heterozygous	D	V3-30.3	99.4	C	C
							D1-7
B-CLL66	N	WT	210ins2bp	Acq	Heterozygous	D	V3-11	100	C	E/C
							D3-9
B-CLL46^†	N	WT	A701G	G	Heterozygous	D	V3-21	94.6	C	F
(Li-Fraumeni)			(Y234C)				D2-9

Tumor	ATM protein	ATM mutation	TP53mutation (amino acid change)	Germline/ somatic	Allelic status	p53/MDM2/p21 induction	VH/D/J family	% Homology	Stage	Th
B-CLL9	N	WT	C844T	Acq	Hemizygous	D	V3-30.3	100	B	C/P
			(R282W)				D3-22/J6
B-CLL43^*	N	WT	C472G	Acq	Hemizygous	D	VH5-51	100	C	CPFCy
			(R158G)				D3-10
B-CLL44^*	N	WT	G412C	Acq	Hemizygous	ND	V1-69	99.6	C	NA
			(A138P)				Dns/J5
B-CLL45	N	WT	1207ins133bp	Acq	Heterozygous	D	V3-30.3	99.4	C	C
							D1-7
B-CLL66	N	WT	210ins2bp	Acq	Heterozygous	D	V3-11	100	C	E/C
							D3-9
B-CLL46^†	N	WT	A701G	G	Heterozygous	D	V3-21	94.6	C	F
(Li-Fraumeni)			(Y234C)				D2-9

For abbreviations, see Table 1.

Patients with tumors B-CLL 43 and 44 were identical twins.

Patient with B-CLL 46 had Li Fraumeni syndrome.

Cy indicates cyclophosphamide.